Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 2548 results for methods

  1. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

  2. Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (TA1092)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.

  3. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

  4. Guselkumab for treating moderate to severe plaque psoriasis (TA521)

    Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.

  5. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  6. AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)

    NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .

  7. Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

    Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.

  8. Preterm labour and birth (NG25)

    This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

  9. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

  10. Acute heart failure: diagnosis and management (CG187)

    This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.

  11. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  12. Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)

    NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms

  13. Ex-situ machine perfusion devices for deceased donor liver transplants

    In development Reference number: GID-HTE10066 Expected publication date:  20 August 2026

  14. Self-harm: assessment, management and preventing recurrence (NG225)

    This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.